

Drug Utilization Review Board

Oklahoma Health Care Authority
4545 N. Lincoln Suite 124
Oklahoma City, Oklahoma 73105
OHCA Board Room

November 9, 2005 @ 6:00 p.m.



THE UNIVERSITY OF
OKLAHOMA



THE UNIVERSITY OF OKLAHOMA

MEMORANDUM

TO: Drug Utilization Review Board Members
FROM: Shellie Gorman, Pharm.D.
SUBJECT: **Packet Contents for Board Meeting – November 9, 2005**
DATE: November 2, 2005
NOTE: **THE DUR BOARD WILL MEET AT 6:00 P.M.**

Enclosed are the following items related to the November meeting. Material is arranged in order of the Agenda.

Call to Order

Public Comment Forum

Action Item – Approval of DUR Board Meeting Minutes – **See Appendix A.**

Update on DUR/MCAU Program – **See Appendix B.**

Action Item – Vote to Prior Authorize Rozerem™ – **See Appendix C.**

Action Item – Vote to Prior Authorize Ambien CR™ – **See Appendix D.**

Analysis of Non-Dual Claim Utilization – **See Appendix E**

Review and Discuss Asthma Utilization – **See Appendix F**

Action Item – Annual Review of Non-Sedating Antihistamines– **See Appendix G**

Review and Discuss Nasal Anti-Allergy Products – **See Appendix H.**

New Product Reviews and Notices – **See Appendix I.**

30 Day Notice to Prior Authorize Xopenex HFA™, Darvocet A500™ and Balacet 325™

FDA and DEA Updates – **See Appendix J.**

Future Business

Adjournment

Drug Utilization Review Board
(DUR Board)
Meeting – November 9, 2005 @ 6:00p.m.

Oklahoma Health Care Authority
4545 N. Lincoln Suite 124
Oklahoma City, Oklahoma 73105
Oklahoma Health Care Authority Board Room

AGENDA

Discussion and Action On the following Items:

Items to be presented by Dr. Whitsett, Chairman:

- 1. Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. Whitsett, Chairman:

- 2. Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Item

Items to be presented by Dr. Whitsett, Chairman:

- 3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. September 14, 2005 DUR Minutes – Vote
 - B. Memorandum of September 14, 2005 DUR Recommendations
 - C. Provider Correspondence

Items to be presented by Dr. Flannigan, Dr. Whitsett, Chairman:

- 4. Update on DUR/MCAU Program – See Appendix B.**
 - A. Retrospective Drug Utilization Review for July 2005
 - B. Medication Coverage Activity Audit for September and October 2005
 - C. Help Desk Activity Audit for September and October 2005

Items to be presented by Dr. Browning, Dr. Whitsett, Chairman:

- 5. Action Item – Vote to Prior Authorize Rozerem™ – See Appendix C.**
 - A. Product Summary
 - B. COP Recommendations

Items to be presented by Dr. Gorman, Dr. Whitsett, Chairman:

- 6. Action Item – Vote to Prior Authorize Ambien CR™ – See Appendix D.**
 - A. Product Summary
 - B. COP Recommendations

Items to be presented by Dr. Gorman, Dr. Whitsett, Chairman:

- 7. Analysis of Non-Dual Claim Utilization – See Appendix E.**
 - A. Background
 - B. Utilization Review
 - C. Discussion

Items to be presented by Dr. Flannigan, Dr. Whitsett, Chairman:

- 8. Review and Discuss Asthma Utilization – See Appendix F.**
 - A. Product Information
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Gorman, Dr. Whitsett, Chairman:

- 9. Action Item – Annual Review of Non-Sedating Antihistamines – See Appendix G.**
 - A. Current Prior authorization Criteria
 - B. Utilization Review
 - C. Anticipated Market Changes to Class
 - D. COP Recommendations

Items to be presented by Dr. Gorman, Dr. Whitsett, Chairman:

- 10. Review and Discuss Nasal Anti-Allergy Products – See Appendix H.**
 - A. Product Information
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Flannigan, Dr. Moore, Dr. Gorman, Dr. Whitsett, Chairman:

- 11. New Product Reviews and Notices – See Appendix I.**
 - A. **30 Day Notice to Prior Authorize Xopenex HFA™**
 - B. **30 Day Notice to Prior Authorize Darvocet A500™ and Balacet 325™**
 - C. New Product Summaries
- 12. FDA and DEA Updates – See Appendix J.**
- 13. Future Business**
 - A. Antipsychotic Utilization Review
 - B. Anticonvulsant Review
 - C. Muscle Relaxant Review
 - D. Osteoporosis Review
 - E. Contraceptive Utilization Review
 - F. Antidiabetic Utilization Review
 - G. Antiinfectives Utilization Review
 - H. Annual Reviews
 - I. New Product Reviews
- 14. Adjournment**

Addendum
to
APPENDIX B




Retrospective Drug Utilization Review Report


Claims Reviewed for July 2005

Module	Drug Interaction	Duplication of Therapy	Drug-Disease Precautions	Dosing & Duration
Total # of <u>messages</u> returned by system when <u>no limits</u> were applied	70,720	69,645	742,374	37,993
<u>Limits</u> which were applied	Established, major, age 0 - 21	Narcotics, Abuse potential only, age 0-21	Contraindicated, age 0-21, with Epilepsy	High dose, Narcotic agonists
Total # of <u>messages</u> after <u>limits</u> were applied	10	230	72	6
Total # of <u>clients</u> reviewed after <u>limits</u> were applied	10	173	48	6
LETTERS				
Prescribers		Pharmacies		
Sent	Responded	Sent	Responded	
101	36	45	29	

PRIOR AUTHORIZATION ACTIVITY REPORT October 2005



PRIOR AUTHORIZATION REPORT September 2004 - October 2005



Activity Audit for

October 01 2005 Through October 31 2005

Date	Anxiolytic/ Hypnotics		Antihistamine		Growth Hormones		Stimulant		Nsaids		ACE Inhibitors		HTN Combos		Calcium Channel Blockers		Plavix		ARB		Anti- depressants		Daily Total
	app.	den.	app.	den.	app.	den.	app.	den.	app.	den.	app.	den.	app.	den.	app.	den.	app.	den.	app.	den.	app.	den.	
App.	13	2824	9	260	1084	32	913	200	217	41	40	11	89	572	29	5	245						
Den.																							
Average Length of Approvals in Days	17	97	99	168	204	174	119	100	186	200	105	127	105	105	105	105	105	105	105	105	105	105	

Changes to existing PA's

963	963
Total (Previous Year)	17534

*** Denial Codes**

762 = Lack of clinical information	12.26%
763 = Medication not eligible	2.16%
764 = Existing PA	1.69%
772 = Not qualified for requested Tier	8.97%
773 = Requested override not approved	14.98%

SUPER PA's

Admitted to Nursing Home	1
Early Refill Attempts	46318
Dosing Change	618
High Dose	39
Lost/Broken Rx	120
Stolen	23
Other	67
Wrong D.S. on Previous Rx	22
Quantity vs. Days Supply	1733
Brand	222
-- Approved	74
-- Denied	35

Monthly Totals


Approved	7914	Percent of Total	60.54%
Additional PA's	27		0.21%
Emergency PA's	6		0.05%
Duplicates	605		4.63%
Incompletes	2391		18.29%
Denied *	2129		16.29%
Total	13072		100.00%

Daily Average of 622.48 for 21 Days

Changes to existing PA's: Backdates, changing units, end dates, etc.
 Additional PA's: Done by the help desk (doctor letter responses, PA ran for the wrong person)
 Incompletes: Missing necessary information (NDC, SIG, Diagnosis, etc.)

CALL VOLUME MONTHLY REPORT

September 2004 - October 2005



CALL VOLUME ISSUES

September 2004 - October 2005

